

Special Issue

Synthesis, Structure and Evaluation of Anticancer Heterocycles and Related Organometallic Derivatives

Message from the Guest Editor

Versatile heterocyclic compounds with characteristic structural motifs constitute the vast majority of FDA-approved anticancer agents used in therapy and tested in different stages of clinical trials. We intend for this Special Issue to be a collection of high-standard original contributions and reviews highlighting the most recent achievements and up-to-date trends in the synthetic strategies and methodologies aiming at the rational design and development of novel antiproliferative heterocycles with organometallic units. Articles reporting on physicochemical investigations (e.g., electrochemical analysis), spectroscopic and theoretical modeling studies, comparative evaluation and interpretation of the activity of organometallic models and their purely organic counterparts with disclosed structure–activity relationships are also welcome in this Special Issue.


Guest Editor

Prof. Dr. Antal Csampai

Institute of Chemistry, Faculty of Science, Eötvös Loránd University (ELTE), Pázmány Péter sétány 1/A, 1117 Budapest, Hungary

Deadline for manuscript submissions

closed (30 November 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed




mdpi.com/si/130922

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).